PLP2 Inhibitors
Chemical inhibitors of PLP2 can exert their inhibitory effects through various biochemical and cellular pathways. Cyclosporin A, for example, binds to cyclophilins leading to the inhibition of calcineurin. Since calcineurin is essential for T-cell activation, and PLP2 plays a role in immune response modulation, this inhibition can decrease the immune pathways that involve PLP2, leading to its functional inhibition. Similarly, Rapamycin interacts with FKBP12 to inhibit mTOR, a key regulator of cell growth and proliferation. Given PLP2's association with cell growth pathways, the inhibition of mTOR can reduce the cellular processes that PLP2 influences. WZB117, by inhibiting GLUT1, decreases glucose uptake into cells, which is necessary for the glycosylation processes that PLP2 is known to regulate. Therefore, the reduced glucose entry can lower the glycosylation of proteins, indirectly inhibiting the functional role of PLP2.
Further, PD98059 targets MEK in the MAPK pathway, an upstream effector of ERK, whose signaling cascades involve PLP2. By inhibiting MEK, PD98059 can diminish the signaling processes dependent on the function of PLP2. LY294002, as a PI3K inhibitor, can decrease activities in the PI3K/AKT/mTOR pathway, thus reducing PLP2's cellular activities. Brefeldin A disrupts the Golgi apparatus structure and function, inhibiting protein transport-a process where PLP2 is involved, thereby inhibiting its function. Monensin, by altering lysosomal pH, disrupts secretory pathways. Since PLP2 is involved in protein trafficking, Monensin's action can inhibit PLP2's function in these processes. Genistein, Gö6983, and Tyrphostin AG 1478 are kinase inhibitors that interfere with phosphorylation and signaling pathways that PLP2 is part of, therefore inhibiting the protein's function. Triacsin C inhibits long-chain acyl-CoA synthetase, reducing lipid biosynthesis and modification, which are processes involving PLP2, thus inhibiting its role. Lastly, Chloroquine affects vesicle pH, impacting protein sorting and maturation, pathways in which PLP2 functions, thereby inhibiting its role.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $62.00 $90.00 $299.00 $475.00 $1015.00 $2099.00 | 69 | |
Cyclosporin A binds to cyclophilins and inhibits calcineurin, which is crucial for T-cell activation. Since PLP2 has been implicated in immune response modulation, Cyclosporin A's action on T-cells can attenuate the immune pathways that PLP2 is involved in, leading to its functional inhibition. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin forms a complex with FKBP12 and inhibits mTOR, a key regulator of cell growth and proliferation. PLP2 is associated with pathways involving cell growth, and thus inhibition of mTOR can decrease the functional activity of PLP2 by reducing the cellular processes it influences. | ||||||
Wiskostatin | 253449-04-6 | sc-204399 sc-204399A sc-204399B sc-204399C | 1 mg 5 mg 25 mg 50 mg | $48.00 $122.00 $432.00 $812.00 | 4 | |
WZB117 inhibits glucose transporter 1 (GLUT1), reducing glucose uptake in cells. Given that PLP2 is involved in the regulation of glycosylation processes, hindering glucose entry can decrease the glycosylation of proteins and indirectly inhibit the functional role of PLP2 in this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which acts upstream of ERK in the MAPK pathway. As PLP2 is involved in signaling cascades, the inhibition of MEK, and consequently ERK, can diminish the signaling processes that rely on the function of PLP2. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of PI3K, which is involved in the PI3K/AKT/mTOR signaling pathway. Inhibition of this pathway can reduce the cellular activities that PLP2 is implicated in, thereby functionally inhibiting PLP2. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $30.00 $52.00 $122.00 $367.00 | 25 | |
Brefeldin A disrupts the structure and function of the Golgi apparatus, inhibiting protein transport. As PLP2 is involved in protein modification and trafficking, the disruption of Golgi function can lead to functional inhibition of PLP2's role in these processes. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $152.00 $515.00 | ||
Monensin is an ionophore that disrupts lysosomal pH and inhibits secretory pathways. By disrupting these pathways, Monensin can inhibit the intracellular trafficking of proteins, a process in which PLP2 is functionally involved. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein is a tyrosine kinase inhibitor, and its activity can inhibit the phosphorylation of proteins involved in signaling pathways. Since PLP2 is associated with such pathways, the inhibition of protein phosphorylation can functionally inhibit PLP2. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $103.00 $293.00 $465.00 | 15 | |
Gö6983 is a protein kinase C (PKC) inhibitor. PKC is involved in the regulation of various signaling pathways. Inhibition of PKC can diminish the signaling cascades that PLP2 is part of, thus functionally inhibiting PLP2. | ||||||
Triacsin C Solution in DMSO | 76896-80-5 | sc-200574 sc-200574A | 100 µg 1 mg | $149.00 $826.00 | 14 | |
Triacsin C inhibits long-chain acyl-CoA synthetase, which can reduce lipid biosynthesis and modification. As PLP2 is implicated in lipid-related processes, inhibition of this enzyme can decrease PLP2's functional role in these pathways. | ||||||